KdT Ventures Announces Oversubscribed Fund IV to Invest in Early-Stage Frontier Science Companies

- Fund IV is the firm's largest fund to date, with total assets under management in excess of $250 million.

- Firm promotes Phil Grayeski, Ph.D., to Managing Partner and Patrick Malone, M.D., Ph.D., to Partner

KdT Ventures Announces Oversubscribed Fund IV to Invest in Early-Stage Frontier Science Companies

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

KdT Ventures today announced the successful close of its oversubscribed fourth fund (Fund IV), raising over $100 million to support early-stage, science-driven companies. Fund IV is the firm’s largest fund to date, and follows KdT’s previous $80 million Fund III which was announced in 2022. The firm’s total assets under management now exceed $250 million.

“Scientific breakthroughs are rapidly transforming our physical world, and we remain committed to backing the most ambitious founders who are harnessing these advances to build groundbreaking companies,” said Cain McClary, M.D., Founder and Managing Partner, KdT Ventures. “Our investments target technical founders who are leveraging cutting-edge chemistry, biology, compute and other scientific disciplines to create revolutionary products and technologies.”

KdT will remain focused on companies applying cutting-edge technologies to physical systems, covering diverse sectors ranging from therapeutics, digital health, industrial biotechnology, and climate at the earliest stages of inception. In recent years, most venture capital firms have taken the path of raising successively larger funds, requiring the deployment of larger and thus later-stage checks to drive returns. As an early-stage fund, KdT believes the current fund size allows the firm to remain committed to its mission of supporting scientific innovations at the earliest stages of inception.

“Our team’s unique scientific and operational experience provides strategic insights at inception to maximize the potential of technological platforms across the diverse verticals covered by the firm,” said Phil Grayeski, Ph.D., Managing Partner, KdT Ventures. “In practice, we’ve repeatedly demonstrated our ability to find and support disruptive companies across each vertical of focus.”

By partnering with founders at the earliest stages, KdT Ventures often provides the first institutional investment in a company, writing initial checks ranging from $500,000 to $5 million. The firm also has the capacity to evaluate later-stage opportunities, leveraging its institutional LP base for larger investments.

“Our approach has always been to find and support entrepreneurs who are solving complex challenges by leveraging the convergence of computational tools and science,” said Mack Healy, J.D., Managing Partner, KdT Ventures. “With our deep technical expertise, outsized team and relentless desire to be the best early stage science firm, we’re well positioned to provide the hands-on support that founders need to build transformative companies.”

Leadership Team Expansion

As part of its growth strategy, KdT is announcing two key promotions:

Phil Grayeski, Ph.D., has been promoted to Managing Partner. Phil has played a pivotal role in shaping KdT's investment strategy since Fund I in March 2018, with significant experience in biotechnology and genetic medicine. Phil was previously involved with spinning out several biotechnology companies from academia, including Torque Bio, StrideBio, and Ribometrix, as an early operator and founder.
Patrick Malone, M.D., Ph.D., has been promoted to Partner. He brings expertise in neuroscience and machine learning, and started his investment career at Northpond Ventures.

Founded by Cain McClary in 2017, KdT Ventures features an investment team of “Scientific Athletes,” with 9 advanced degrees, 48 years of combined graduate scientific and clinical training, and experience co-founding 4 biotechnology companies. Additionally, the breadth of the KdT portfolio, which now stands at over 65 companies across multiple physical layer supply chains, enables deep market understanding and creative insights at the convergence of legacy industries. This unique blend of technical expertise and entrepreneurial acumen allows KdT to provide deep technical and strategic support to a select few early-stage investments annually, enabling portfolio company growth.

About KdT Ventures

KdT Ventures is an early-stage venture capital firm focused on investing in science-driven companies at the intersection of technology and the physical world. Based in Austin, TX, and Research Triangle, NC, KdT partners with founders in biotechnology, healthcare, sustainability, and beyond, offering deep technical and strategic support to build transformative companies. For more information visit www.kdtvc.com. Follow us @KdT_Ventures.